Hypericin Alleviates Chronic Kidney Disease-induced Left Ventricular Hypertrophy by Regulation of FGF23-FGFR4...

Area of Science:

• Cardiovascular Research
• Nephrology
• Pharmacology

Background:

• Chronic kidney disease (CKD) is a major global health issue linked to cardiovascular complications, especially left ventricular hypertrophy (LVH).
• Fibroblast growth factor 23 (FGF23) is a key hormone implicated in CKD-associated LVH, acting via the fibroblast growth factor receptor 4 (FGFR4) pathway.
• Targeting the FGFR4 signaling pathway presents a therapeutic strategy for managing cardiac dysfunction in CKD.

Purpose of the Study:

• To investigate the potential of Hypericin, a compound from Hypericum perforatum, in treating CKD-induced LVH.
• To elucidate the molecular mechanisms by which Hypericin affects the FGFR4/PLCγ1 signaling pathway in cardiac cells.

Main Methods:

• In vitro studies using rat cardiac myocyte H9c2 cells treated with FGF23.
• In vivo studies utilizing mouse models on a high-phosphate diet and rat models of 5/6 nephrectomy.
• Analysis of the FGFR4/PLCγ1/calcineurin/NFAT3 signaling pathway modulation by Hypericin.

Main Results:

• Hypericin effectively inhibited FGF23-induced cardiac hypertrophy and fibrosis in vitro.
• Hypericin demonstrated therapeutic effects against CKD-induced LVH in vivo.
• The compound's action was attributed to the suppression of the FGFR4/PLCγ1/calcineurin/NFAT3 signaling pathway.

Conclusions:

• Hypericin shows significant therapeutic potential for treating CKD-induced cardiomyopathy.
• By targeting the FGFR4/PLCγ1 pathway, Hypericin can attenuate LVH and myocardial fibrosis in CKD.
• Hypericin represents a promising candidate for novel therapeutic interventions in CKD-related cardiac dysfunction.